Bristol Myers Squibb Q3 2025 Earnings Report

Bristol Myers Squibb EPS Results

• Actual EPS: N/A
• Consensus EPS: $1.65
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Bristol Myers Squibb Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $11.75 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bristol Myers Squibb Announcement Details

• Quarter: Q3 2025
• Date: 10/30/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, October 30, 2025
• Conference Call Time: 8:00AM ET

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company dedicated to discovering, developing and delivering innovative medicines for patients with serious diseases. The company’s research and development efforts are primarily focused on oncology, immunology, cardiovascular disease and fibrosis. Through a combination of internal research programs and strategic acquisitions, Bristol Myers Squibb aims to address critical unmet medical needs and improve long-term health outcomes.

The company’s portfolio includes a range of marketed therapies such as Opdivo for multiple cancers, Eliquis for stroke prevention in atrial fibrillation and various immunology treatments. Following its acquisition of Celgene, Bristol Myers Squibb also integrated several hematology and oncology products, further strengthening its position in specialized medicine. Its pipeline features both small molecules and biologics, with ongoing clinical trials exploring novel mechanisms of action across a spectrum of disease areas.

Founded in 1989 through the merger of Bristol-Myers Company and Squibb Corporation—and tracing its roots back to the mid-19th century—Bristol Myers Squibb is headquartered in New York and operates in more than 60 countries worldwide. The company maintains research facilities in North America, Europe and Asia, and collaborates with academic institutions, biotechnology firms and other pharmaceutical companies to advance scientific innovation. Under the leadership of Chief Executive Officer Giovanni Caforio, Bristol Myers Squibb continues to pursue a patient-centric strategy aimed at delivering transformative therapies on a global scale.